United States: The Federal Circuit's First Enablement Decision Since Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

26 Sep 2023 0 shares 1 views

United States: The Federal Circuit's First Enablement Decision Since Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

Published 26 Sep 2023

Federal Circuit applied Amgen v. Sanofi, 598 U.S. 594 (2013)in deciding that claims 1-4, 19 and 20 of Baxalta's hemophilia patent, U.S. Patent 7,033,590 (‘590)...

Full Article

United States: In Re Cellect – ODP Defense Does Not Impact The Expiration Date Of A Patent With Both PTA And PTE In The Absence Of A Terminal Disclaimer - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq 18 Sep 2023

The Federal Circuit in In re Cellect, Appeals Nos. 2022-1293, 2022-1294, 2022-1295, 2022-1296 held that the earliest patent to..

United States: Federal Circuit Determines Anticipation Of Dependent Claims And Sufficient Evidence Of Commercial Success - Oblon, McClelland, Maier & Neustadt, L.L.P
Mondaq 07 Sep 2023
United States: Federal Circuit Reiterates What Constitutes A Motivation To Combine, A Reasonable Expectation Of Success, And Unexpected Results In New Chemical Compounds - Oblon, McClelland, Maier & Neustadt, L.L.P
Mondaq 01 Sep 2023

United States: The Federal Circuit's First Enablement Decision Since Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

United States: The Federal Circuit's First Enablement Decision Since Amgen - Oblon, McClelland, Maier & Neustadt, L.L.P

You might like

Related news coverage

United States: In Re Cellect – ODP Defense Does Not Impact The Expiration Date Of A Patent With Both PTA And PTE In The Absence Of A Terminal Disclaimer - Oblon, McClelland, Maier & Neustadt, L.L.P

Advertisement